What is Roth Capital’s Forecast for CLRB FY2029 Earnings?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Equities research analysts at Roth Capital issued their FY2029 earnings per share estimates for Cellectar Biosciences in a research report issued on Thursday, March 13th. Roth Capital analyst J. Aschoff expects that the biopharmaceutical company will post earnings per share of $0.21 for the year. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.59) per share.

Several other equities analysts have also weighed in on CLRB. LADENBURG THALM/SH SH initiated coverage on shares of Cellectar Biosciences in a research report on Thursday, December 5th. They set a “buy” rating and a $13.00 price target for the company. Oppenheimer reiterated a “market perform” rating on shares of Cellectar Biosciences in a research note on Wednesday, December 11th. Finally, StockNews.com started coverage on shares of Cellectar Biosciences in a research note on Tuesday. They set a “sell” rating for the company.

Cellectar Biosciences Price Performance

Shares of NASDAQ:CLRB opened at $0.34 on Monday. Cellectar Biosciences has a 1 year low of $0.22 and a 1 year high of $4.17. The company has a market capitalization of $15.52 million, a PE ratio of -0.20 and a beta of 0.96. The business has a fifty day moving average price of $0.29 and a two-hundred day moving average price of $1.14.

Institutional Investors Weigh In On Cellectar Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. bought a new position in Cellectar Biosciences during the third quarter worth about $27,000. JPMorgan Chase & Co. lifted its stake in shares of Cellectar Biosciences by 687.3% during the 4th quarter. JPMorgan Chase & Co. now owns 182,403 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 159,234 shares in the last quarter. Bank of America Corp DE boosted its holdings in Cellectar Biosciences by 25.3% in the 4th quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 41,704 shares during the period. Geode Capital Management LLC grew its stake in Cellectar Biosciences by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock valued at $754,000 after buying an additional 11,266 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Cellectar Biosciences in the 4th quarter valued at approximately $156,000. 16.41% of the stock is currently owned by institutional investors.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.